Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18671876 | 1.00 | LMNA (0.42) | LMNAKMT2AALDH1A1HSD17B10MEN1 | |
| SCHEMBL18671790 | 1.00 | LMNA (0.42) | LMNAKMT2AALDH1A1HSD17B10MEN1 | |
| SCHEMBL22851219 | 0.98 | LMNA (0.41) | LMNAKMT2AALDH1A1HSD17B10MEN1 | |
| SCHEMBL19352786 | 0.90 | LMNA (0.46) | LMNAKMT2AALDH1A1HSD17B10MEN1 | |
| SCHEMBL19353086 | 0.88 | LMNA (0.50) | LMNAKMT2AALDH1A1HSD17B10MEN1 | |
| SCHEMBL19966768 | 0.88 | LMNA (0.44) | LMNAKMT2AALDH1A1HSD17B10MEN1 | |
| SCHEMBL21790560 | 0.86 | LMNA (0.48) | LMNAKMT2AALDH1A1HSD17B10MEN1 | |
| SCHEMBL24045162 | 0.85 | EPHX1 (0.39) | ALDH1A1TSHRGGPS1FDPS | |
| SCHEMBL20643823 | 0.85 | EPHX1 (0.44) | ALDH1A1TSHRGGPS1FDPS | |
| SCHEMBL18525926 | 0.85 | EPHX1 (0.39) | ALDH1A1TSHRGGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | LMNA 3691/4885KMT2A 3048/4885ALDH1A1 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.